Heparin After Thrombolysis in STEMI
Continue anticoagulation with unfractionated heparin (UFH) for 48 hours after fibrinolytic therapy, or preferably switch to enoxaparin for the duration of hospitalization up to 8 days, as enoxaparin demonstrates superior efficacy in reducing death and reinfarction without increased intracranial bleeding risk. 1, 2, 3, 4
Anticoagulation Strategy Post-Thrombolysis
First-Line Recommendation: Enoxaparin (Preferred)
Enoxaparin is superior to UFH when used as adjunctive therapy following fibrinolysis 1, 2, 3. The dosing regimen is:
- Age <75 years: 30 mg IV bolus, followed 15 minutes later by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first 2 doses) 1, 3
- Age ≥75 years: No bolus; 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for first 2 doses) 1, 3
- Renal impairment (CrCl <30 mL/min): 1 mg/kg subcutaneously every 24 hours 1, 3
- Duration: Continue for index hospitalization, up to 8 days or until revascularization 1, 2, 3
The evidence supporting enoxaparin comes from the ExTRACT-TIMI 25 trial, which demonstrated a significant reduction in death or nonfatal MI (9.9% vs 12.0%) compared to UFH, with acceptable bleeding rates 4.
Alternative: Unfractionated Heparin
If enoxaparin is not available or contraindicated, UFH remains acceptable 5, 3:
- Initial bolus: 60 U/kg IV (maximum 4000 U) 2, 3, 6
- Infusion: 12 U/kg/hour (maximum 1000 U/hour) 2, 3, 6
- Target aPTT: 1.5-2.0 times control (approximately 50-70 seconds) 2, 3, 6
- Duration: 48 hours or until revascularization 2, 3
- Monitoring: Check aPTT every 4 hours initially, then at appropriate intervals 6
Fondaparinux Option
Fondaparinux can be used but has specific limitations 1, 3:
- Dosing: 2.5 mg IV initial dose, then 2.5 mg subcutaneously daily for up to 8 days 1, 3
- Contraindication: CrCl <30 mL/min 1, 3
- Critical caveat: Fondaparinux should NEVER be used as sole anticoagulant if PCI is planned due to catheter thrombosis risk; must add UFH with anti-IIa activity 5
Transitioning to PCI After Fibrinolysis
If UFH Was Used
Continue UFH through PCI with additional IV boluses to maintain therapeutic ACT 5:
- Target ACT without GP IIb/IIIa inhibitor: 250-300 seconds (HemoTec) or 300-350 seconds (Hemochron) 5
- Target ACT with GP IIb/IIIa inhibitor: 200-250 seconds 7
If Enoxaparin Was Used
Timing-based dosing strategy 5, 7, 2, 5:
- Last dose <8 hours ago: No additional anticoagulation needed 5, 7, 2, 5
- Last dose 8-12 hours ago: Give 0.3 mg/kg IV bolus 5, 7, 2, 5
- Last dose >12 hours ago: Treat as if no prior anticoagulation
If Fondaparinux Was Used
Mandatory: Add UFH or another anticoagulant with anti-IIa activity before PCI 5, 2, 5
Critical Dosing Pitfalls
Weight-Based Dosing Is Essential
Nearly 50% of patients receive excess heparin doses when weight-based dosing is not followed, particularly in low-body-weight patients and women 8. Excess dosing (>60 U/kg bolus or >12 U/kg/hour infusion) significantly increases bleeding risk without added benefit 8.
Avoid Anticoagulant Switching
Do not switch between anticoagulants (e.g., from enoxaparin to UFH or vice versa) during the same hospitalization, as this increases bleeding risk 7, 4. The SYNERGY trial demonstrated higher bleeding rates in patients who crossed over between anticoagulants 7.
Duration of Therapy
- Medical management only: Continue anticoagulation for 48 hours (UFH) or up to 8 days (enoxaparin/fondaparinux) 1, 2, 3
- If PCI performed: Continue through procedure as outlined above 5
- Post-PCI: No routine continuation of heparin infusion needed, especially if GP IIb/IIIa inhibitors used 7
Monitoring Requirements
- Baseline: aPTT, INR, platelet count 6
- During UFH therapy: aPTT every 4 hours initially, then per protocol 6
- Throughout therapy: Periodic platelet counts, hematocrit, stool occult blood 6
- Enoxaparin/fondaparinux: No routine coagulation monitoring required 1, 3
Evidence Quality Note
The 2025 ACC/AHA guidelines 4 and 2018 ESC guidelines 1 provide the most current recommendations, both strongly favoring enoxaparin over UFH based on Level A evidence from the ExTRACT-TIMI 25 trial. The 2013 ACCF/AHA guidelines 5, 3 established the framework that remains valid, with enoxaparin receiving Class I, Level A/B recommendations.